Valeant: Will Earnings Even Matter?

Shares of Valeant Pharmaceuticals International (VRX) have shed three-quarters of their value during the past 12 months. And it has so many issues, ranging from its massive debt load to its struggles to sell assets, that it’s fair to wonder whether its earnings even matter anymore.

But Valeant is scheduled to report earnings next month, and analysts are already beginning to offer their thoughts. Consider this from JPMorgan’s Chris Schott and team:
Source: Barrons

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>